Drug reference

Ibritumomab

Monoclonal Antibody · Antineoplastic

Also known as Ibritumomab tiuxetan, 90Yttrium (90Y) ibritumomab tiuxetan, Y-ibritumomab tiuxetan, ZEVALIN

Monoclonal AntibodyAntineoplastic

CDSCO approvedSchedule H

EXCRETION

—

not curated

INTERACTIONS

12 major

SEVERE in our sources

PREGNANCY

—

not curated

Top interactionssee all 12 →

AbciximabSevereDatabaseDDInter
AcalabrutinibSevereDatabaseDDInter
AdalimumabSevereDatabaseDDInter
AlteplaseSevereDatabaseDDInter

Mechanism

Ibritumomab is an anti-CD20 murine monoclonal antibody. It is labeled with isotopic yttrium (90Y) or 111In. The radiation from the coupled isotope provides the major antitumor activity of this drug, leading to cell death.

Indications

Relapsed or refractory low-grade, follicular, or B-cell non-Hodgkin lymphomaRituximab-refractory follicular diseaserelapsed lymphoma

Dosing

Adult: Used in conjunction with rituximab in a two-step therapeutic regimen.

Pharmacokinetics

Half-life

short

Side effects

Serious

antibody-related hypersensitivity
bone marrow suppression
secondary leukemias

Drug interactions

Abciximab

Severe

Database

Clinical effect not specified

Source: DDInter

Acalabrutinib

Severe

Database

Drug interaction classified as: synergy

Source: DDInter

Adalimumab

Severe

Database

Drug interaction classified as: synergy

Source: DDInter

Alteplase

Severe

Database

Clinical effect not specified

Source: DDInter

Anagrelide

Severe

Database

Drug interaction classified as: synergy

Source: DDInter

Anisindione

Severe

Database

Drug interaction classified as: synergy

Source: DDInter

Anistreplase

Severe

Database

Clinical effect not specified

Source: DDInter

Antithrombin Alfa

Severe

Database

Clinical effect not specified

Source: DDInter

Antithrombin Iii Human

Severe

Database

Clinical effect not specified

Source: DDInter

Apixaban

Severe

Database

Drug interaction classified as: synergy

Source: DDInter

Ardeparin

Severe

Database

Clinical effect not specified

Source: DDInter

Argatroban

Severe

Database

Clinical effect not specified

Source: DDInter

Related guidelines

Coeliac disease

OTHER · Gastroenterology · 2016

Inflammatory bowel disease

OTHER · Gastroenterology · 2015

Chronic kidney disease — assessment and management

KDIGO · Nephrology · 2024

Glomerular diseases

KDIGO · Nephrology · 2021

Chronic kidney disease — assessment and management

NICE · Nephrology · 2021

Other Monoclonal Antibody drugs

Ask House about Ibritumomab

Continue into a citation-backed clinical answer with the drug context already attached.

Open in workspace Ask House about this drug

Sources: Goodman & Gilman 14e, Katzung·Verified: 2026-05-10 · House clinical team